Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Merck’s Reserves $950 Million for Vioxx Crime Probe

Don't Miss Out —
Follow us on:

Oct. 29 (Bloomberg) -- Merck & Co. set aside $950 million to resolve a criminal probe into the Vioxx painkiller it withdrew six years ago, raising potential legal costs to $7.7 billion and driving down the company’s shares by 1.7 percent.

The legal reserve contributed to a 90 percent decline in third-quarter income to $342 million, the Whitehouse Station, New Jersey-based drugmaker said today in a statement. Merck fell 63 cents, to $36.31, at 4 p.m. in New York Stock Exchange composite trading.

Merck, the second-biggest U.S. drugmaker, pulled Vioxx from the market in 2004 after a study showed it doubled the risk of heart attacks and strokes. The company previously paid $4.85 billion to settle thousands of lawsuits claiming injuries and another $1.9 billion for legal costs. The new legal reserve will cover an “anticipated resolution” of a probe by U.S. prosecutors into research and marketing of Vioxx.

“We’d be buyers on any significant weakness today from the $950 million legal reserve related to Vioxx,” said Seamus Fernandez, an analyst with Leerink Swann & Co., in a note to clients. The “legal charge overshadows solid product performance.”

Excluding the Vioxx reserve and other one-time items, earnings were 85 cents a share, the company said. Those results beat by 2 cents the average estimate of 15 analysts surveyed by Bloomberg. Sales jumped 84 percent to $11.1 billion after adding products from the $49.6 billion acquisition of Schering-Plough Corp. last November, the company said today in a statement.

Previous Disclosure

Merck previously disclosed that federal prosecutors in Boston had identified the company in March 2009 as a target of a grand jury investigation, and that witnesses had been called in the probe. It also said that certain cities in Europe were weighing whether to bring criminal charges.

“Our discussions with the government are ongoing, and until they’re concluded, there can be no certainty about a definitive resolution,” spokesman Ron Rogers said in an interview.

The company won 11 of 16 Vioxx lawsuits at trial before agreeing in 2007 to create a $4.85 billion settlement fund. It also reserved $1.9 billion for legal costs.

Plaintiffs who sued in state and federal courts claimed Merck didn’t adequately disclose Vioxx safety data to the U.S. Food and Drug Administration, didn’t properly warn doctors and patients of the drug’s risks and misrepresented the potential harm in marketing materials.

To contact the reporters on this story: Tom Randall in New York at; David Voreacos in Newark, New Jersey, at

To contact the editor responsible for this story: Reg Gale at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.